Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Z-206 (mesalazine) in Active Crohn's Disease
jRCT2080221421Phase 2
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of Salcrozine in Crohn's disease, sponsored by Zeria Pharmaceutical Co., Ltd.
02
Drugs
Salcrozine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2080221421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221421.